BioSpace News Archive

Assembly Biosciences, Inc. today announced data from its hepatitis D virus (HDV) and hepatitis B virus (HBV) antiviral pipeline featured in five poster presentations at the International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna, Austria.

HistoIndex today announced that the Company, alongside its collaborators, will present new data on its novel stain-free tissue imaging technology using clinically validated artificial intelligence (AI) algorithms at the EASL Congress, taking place June 21-24, 2023.

Alkermes plc announced that leading proxy advisory firm Glass, Lewis & Co. has recommended that Alkermes shareholders vote the WHITE proxy card “FOR” all seven of Alkermes’ highly qualified director nominees at the Company’s upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.

MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).

Inhibikase Therapeutics, Inc. today announced a physician and patient awareness campaign for its Phase 2 ‘201' program evaluating IkT-148009 as a potentially disease-modifying treatment of Parkinson’s disease.

Quest Diagnostics today announced that it has completed its previously announced acquisition of Haystack Oncology.

CMP Pharma, Inc. announced today that Liqrev (Sildenafil) Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-made oral liquid of sildenafil, is now available.

DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.

Biomerica Inc. announced that the China National Intellectual Property Administration (CNIPA) has issued a Notice of Allowance for a patent application that covers a development stage information technology (“IT”) system.

Sight Sciences, Inc. announced that Cigna Healthcare, has updated its Glaucoma Surgical Procedure policy to cover both ab interno canaloplasty and goniotomy procedures for the treatment of open-angle glaucoma effective June 15, 2023.